| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Differential Expression Levels of Plasma microRNAs in Neuroblastoma Patients Identified by Next-Generation Sequencing |
|
言語 |
en |
| 作成者 |
ARFAN, Ahmad
KURIHARA, Sho
KOJIMA, Masato
KIMURA, Shingo
KANAWA, Masami
SOTOMARU, Yusuke
HIYAMA, Eiso
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
Copyright (c) 2020 Hiroshima University Medical Press |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Neuroblastoma |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
microRNA |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Prognosis |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
NGS |
| 内容記述 |
|
|
内容記述 |
Efforts to identify biomarkers for neuroblastoma (NB) have been ongoing, but no definite biomarker has been identified in peripheral blood. We proposed the use of plasma exosomal miRNAs as biomarkers of unfavorable NB patient outcomes. Exosomal miRNAs isolated from 31 plasma and 37 tissue samples, many from the same NB patients, were sequenced using a next-generation sequencing instrument. We analyzed the correlation between miRNA expression levels in plasma and tissue samples with International Neuroblastoma Risk Group staging system (INRGSS) outcome and MYCN status. We chose differentially expressed miRNAs with similar expression patterns in plasma and tissue samples in each of the three analysis groups and combined those miRNAs to find the optimal combination with the potential to be considered as a biomarker. MicroRNA-92a-3p was found to be significantly upregulated in deceased patients (p = 0.017), miR-375 was upregulated in INRGSS stage M patients (p = 0.002), and plasma miR-92a-3p and miR-99a-5 levels were upregulated in patients with MYCN amplification (p = 0.007 and 0.006). The combination of miR-92a-3p, miR-375, and miR-99a-5p levels was shown to be a statistically significant predictor of NB patient outcomes (AUC = 0.726, p = 0.001, 95% CI = 0.612–0.841, sensitivity = 77%, specificity = 56.7%). Thus, the combination of miR-92a3p, miR-375, and miR-99a-5p may potentially be used as a biomarker for unfavorable NB patient outcomes. However, further validation is required in a larger number of NB patients. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
This research was partially supported by a Grant-in-Aid for Scientific Research (A) (No.19H0105600) from the Ministry of Education, Culture, Sports, Science and Technology. |
| 出版者 |
|
|
出版者 |
Hiroshima University Medical Press |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.24811/hjms.69.2_39 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.24811/hjms.69.2_39 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0018-2052 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2433-7668 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00664312 |
| 開始ページ |
|
|
開始ページ |
39 |
| 書誌情報 |
Hiroshima Journal of Medical Sciences
Hiroshima Journal of Medical Sciences
巻 69,
号 2,
p. 39-45,
発行日 2020-06-30
|
| 旧ID |
49780 |
HiroshimaJMedSci_69_39.pdf (667.7 KB)
